No definition available.

Name:	ions_CollaborativeArrangementAndLicensingAgreementAbstract
Namespace Prefix:	ions_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Cumulative amount of milestone payments, license fees and/or upfront fees received under the collaborative arrangement as of the end of the reporting period.

+ References

No definition available.

+ Details

Name:	ions_CumulativePaymentsAndOrFeesReceived
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the maximum amount of payments receivable under the agreement.

+ References

No definition available.

+ Details

Name:	ions_MaximumAmountOfPaymentsReceivable
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the maximum amount of payments receivable per drug or program under the agreement.

+ References

No definition available.

+ Details

Name:	ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgram
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the next potential milestone payment to be earned.

+ References

No definition available.

+ Details

Name:	ions_NextPotentialMilestonePayment
Namespace Prefix:	ions_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The number of development candidates that must be generated for the brain shuttle program by a mutually agreed deadline to prevent termination by either party under the collaborative arrangement.

+ References

No definition available.

+ Details

Name:	ions_NumberOfDevelopmentCandidatesThatMustBeGeneratedForBrainShuttleProgram
Namespace Prefix:	ions_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

+ Details

Name:	us-gaap_ConcentrationRiskPercentage1
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)
-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 13
-Section A

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 13
-Section A

+ Details

Name:	us-gaap_DeferredRevenueAdditions
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=ions_RocheMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ions_AgreementEnteredIntoInApril2013Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ions_AchievementOfMilestoneAxis=ions_DevelopmentRegulatoryAndCommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=ions_HttMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ions_AchievementOfMilestoneAxis=ions_DevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ions_AchievementOfMilestoneAxis=ions_RegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	ions_AchievementOfMilestoneAxis=ions_CommercializationMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=ions_BrainShuttleProgramMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborative Arrangements and Licensing Agreements, Research, Development and Commercialization Partners - Roche (Details) $ in Thousands	1 Months Ended	3 Months Ended								12 Months Ended
	Apr. 30, 2013 USD ($)	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Sep. 30, 2014 USD ($)	Jun. 30, 2014 USD ($)	Mar. 31, 2014 USD ($)	Dec. 31, 2015 USD ($) Candidate	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue earned		$ 51,571	$ 49,121	$ 120,428	$ 62,583	$ 84,861	$ 44,063	$ 57,076	$ 28,161	$ 283,703	$ 214,161	$ 147,285
Roche [Member] \| Collaborations and Licensing Agreements [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Revenue earned										31,200	8,700	$ 5,100
Deferred revenue		8,800				$ 17,000				$ 8,800	$ 17,000
Roche [Member] \| Collaborations and Licensing Agreements [Member] \| Revenue [Member] \| Strategic Partner [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Concentration percentage										11.00%	4.00%	3.00%
Roche [Member] \| Agreement Entered into in April 2013 [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Upfront fee recorded as deferred revenue	$ 30,000
Maximum amount of payments receivable	362,000
Cumulative payments and/or fees received		52,000								$ 52,000
Next potential milestone	$ 10,000
Roche [Member] \| Agreement Entered into in April 2013 [Member] \| Development, Regulatory and Commercial Milestones [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payments receivable per drug		136,500								136,500
Roche [Member] \| Agreement Entered into in April 2013 [Member] \| HTT [Member] \| Development Milestones [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payments receivable		67,000								67,000
Roche [Member] \| Agreement Entered into in April 2013 [Member] \| HTT [Member] \| Regulatory Milestones [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payments receivable		170,000								170,000
Roche [Member] \| Agreement Entered into in April 2013 [Member] \| HTT [Member] \| Commercialization Milestones [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payments receivable		80,000								80,000
Roche [Member] \| Agreement Entered into in April 2013 [Member] \| Brain Shuttle Program [Member] \| Commercialization Milestones [Member]
Collaborative Arrangement and Licensing Agreement [Abstract]
Maximum amount of payments receivable		$ 50,000								$ 50,000
Number of development candidates that must be generated for brain shuttle program \| Candidate										1